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HIGHLIGHTS 
 The intestinal wall integrity plays a role in the development of metabolic
disorders.
 The influence of obstructive sleep apnea (OSA) on markers of gut barrier
(fatty acid binding protein (I-FABP) and Zonulin) was investigated.
 The I-FABP levels were higher in the presence of OSA.
 Zonulin levels were associated with metabolic parameters.
 Obstructive sleep apnea may be a risk factor for intestinal damage, regardless
of metabolic profile.
Abstract 
Background: Obstructive sleep apnea (OSA) is now being recognized as an additional 
contributing factor to the pathogenesis of obesity-related comorbidities. At the same time, 
there is now increasing evidence to suggest that intestinal wall integrity plays a role in the 
development of metabolic syndrome. In the present study, circulating zonulin and fatty acid 
binding protein (I-FABP) were measured in association with metabolic, hepatic and 
inflammatory parameters. 
Results: Compared with controls, plasma I-FABP levels were significantly higher in patients 
with OSA (571 pg/mL (IQR 290-950) vs 396 pg/mL (IQR 234-559), p=0.04). zonulin levels 
were similar between groups. Significant relationships were observed between zonulin levels 
and waist circumference (p<0.05), glucose (p<0.05) and insulin (p<0.05). In addition, in the 
OSA group, zonulin levels correlated negatively with the mean nocturnal oxygenation 
saturation (p<0.05) and positively with total cholesterol (p<0.05), alanine aminotransferase 
(ALT) (p<0.005), aminotransferase (AST) (p<0.01), gamma glutamyltransferase (GGT) 
(p<0.005) and high-sensitivity C-reactive protein (hs-CRP) (p<0.05). Multivariate analysis 
showed that associations between zonulin and ALT, AST and hs-CRP were attenuated, but 
not eliminated, after adjustment for other variables.  
Conclusions: The results of this study suggest that OSA is a risk factor for intestinal damage, 
regardless of metabolic profile, and that intestinal permeability might be a possible 
contributor to nonalcoholic fatty liver disease in patients with OSA. 








Obstructive sleep apnea syndrome (OSA) is a common disorder that is defined by the 
occurrence of repeated episodes of upper airway obstruction and airflow cessation (apneas) 
that normally lead to intermittent arterial hypoxemia (IH) and sleep disruption [1,2]. The 
effects of these cyclical changes of hypoxemia with reoxygenation are similar to ischemia-
reperfusion injury, and evidence from both animal and human studies have shown a 
predominant role of IH in the pathogenesis of OSA comorbidities [3,4].
Recently, there has been a lot of interest in the role of intestinal wall integrity and gut 
microbiota in the pathogenesis of obesity and its concomitant disease [5,7].
 
Loss of intestinal 
barrier function or changes in gut microbiota both seem to be key ingredients involved in the 
pathogenesis of metabolic disorders [8-10].
 
In the present study, it was hypothesized that 
OSA may affect the intestinal barrier function by altering structure and permeability. 
Repetitive periods of intestinal ischemia reperfusion could result in severe damage to the 
intestinal barrier, thereby allowing translocation of luminal antigens, bacteria, and their toxic 
products from the intestinal lumen to the systemic circulation. In addition, persistently 
increased permeability may be an important contributor to the development of metabolic 
complications. To test this hypothesis a case-control study was performed and two novel gut 
barrier markers were evaluated: intestinal fatty acid binding protein (I-FABP) and zonulin. 
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Plasma I-FABP is a highly sensitive marker for intestinal ischemia. Intestinal fatty acid 
binding proteins are small proteins released into the circulation upon enterocyte membrane 
integrity loss, which makes them useful as plasma markers for enterocyte damage during the 
development and progression of intestinal ischemia-reperfusion [11-13].
 
By contrast, zonulin 
is expressed by viable gut epithelial cells to disassemble tight junctions between cells, and 
increase permeability and macromolecule absorption. Previous studies have claimed a role 
for zonulin and its regulation of intestinal barrier function in the genesis of metabolic 
disorders [10,14,15].  
Methods 
Subjects and ethics 
Patients and controls were recruited from subjects who attended the present sleep unit during 
a period of 2 years. In the present study, two subgroups (patients and controls) of participants 
were retrospectively selected. The final sample comprised 38 patients with OSA and 38 
controls matched for sex, age (±5 years), body mass index (BMI) (±3 kg/m) and the presence 
of metabolic syndrome. 
No participant was under continuous positive airway pressure (CPAP) treatment or suffered 
from any other chronic disease (chronic obstructive pulmonary disease (COPD), liver 
cirrhosis, thyroid dysfunction, rheumatoid arthritis, coronary disease, cardiac failure, chronic 
renal failure and/or psychiatric disorders). There were no differences between the number of 
patients and controls taking hypoglycemic, hypolipemiant and/or antihypertensive agents. No 
participant was regularly taking anti-inflammatory medication. The study was approved by 
the Ethics Committee of the present institution, and all participants signed their consent after 
being fully informed of its goals and characteristics.  
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Measurements and definitions 
The diagnosis of OSA was established by full polysomnography (E-Series Compumedics, 
Abbotsford, Australia) that included recording of oronasal flow, thoracoabdominal 
movements, electrocardiography, submental and pretibial electromyography, 
electrooculography, electroencephalography and transcutaneous measurement of arterial 
oxygen saturation. Apnea was defined by the absence of airflow for >10 seconds. Hypopnea 
was defined as any airflow reduction that lasted >10 seconds and resulted in arousal or 
oxygen desaturation. Desaturation was considered to be a decrease in SaO2 >3%. The apnea-
hypopnea index (AHI) was defined as the sum of the number of apneas plus hypopneas per 
hour of sleep. The case or control status was defined by an AHI threshold of ≥10. Excessive 
daytime sleepiness (EDS) was subjectively quantified by the Epworth sleepiness scale (ESS). 
The occurrence of the metabolic syndrome was analyzed according to the National 
Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III ) clinical criteria 
[16]: (1) waist circumference ≥102 cm in men and ≥88 cm in women; (2) fasting glucose 
≥100 mg/dL; (3) triglycerides ≥150 mg/dL; (4) HDL cholesterol (HDLc) <40 mg/dL in men 
and <50 mg/dL in women; (5) systolic blood pressure (SBP) ≥130 mmHg or diastolic blood 
pressure (DBP) ≥85 mmHg or patient on specific drug treatment. Metabolic syndrome was 
diagnosed if three of these five factors were present. Diabetes was defined by use of diabetes 
medications or a fasting glucose ≥126 mg/mL. Hypertension was diagnosed if the SBP was 
≥140 mmHg and/or DBP was ≥90 mmHg or the individual was on specific treatment. 
Participants were considered obese when their BMI was ≥30 kg/m.  Comment [JM5]: As my previous comment 




After fasting overnight, venous blood samples were obtained between 08:00 and 10:00. 
Blood was centrifuged and serum was immediately separated in aliquots and stored at –80 ºC 
until analysis.  
 
Glucose, triglycerides, total cholesterol, HDLc, creatinine, aspartate aminotransferase (AST), 
alanine aminotransferase (ALT) and gamma glutamyltransferase (GGT) were determined by 
standard enzymatic methods on a Hitachi Modular analyzer (Roche Diagnostics, 
Indianapolis, USA). The high-sensitivity C-reactive protein (hs-CRP) assay was performed 
using a chemiluminescence assay on an Immulite 2000 analyzer (Siemens Medical Solutions 
Diagnostics, NY, USA).  
 
The plasma levels of zonulin and I-FABP were determined by enzyme linked immunosorbent 
assay (ELISA) using commercial kits (zonulin: Immunodiagnostik AG, Bensheim, Germany; 
I-FABP: Hycult Biotechnology, Uden, The Netherlands). Measurements were always 
conducted in duplicate, and mean values were used for analysis. The detection limit for 
zonulin was 0.22 ng/mL and for I-FABP 40 pg/mL. Intra and interassay coefficients of 
variation were between 3-10%. 
 
Statistical analysis 
Results were presented as percentages, mean±standard deviations (SD) or median 
(interquartile range). Skewed variables were logarithmically transformed before analysis 
Patients characteristics were compared using independent sample t-tests for continuous 
measures or repeated measures ANOVA, when appropriate. Categorical variables were 
compared using the Chi-squared or Fisher tests.  
 




Correlations between the subjects’ characteristics and zonulin and I-FABP were explored 
using the Spearman-rank test. Multiple regression analyses were used to confirm the 
significant associations detected with adjustment for age, sex, BMI and metabolic syndrome 
components. 
 
The study was powered not a miss a difference of 1.5 ng/mL in zonulin, assuming a SD of 
2 ng/mL in healthy subjects [14]
 
at a significance level of 5% and with a power of 90%, 
which required 31 subjects in each group. A p-value <0.05 was considered significant. 
Results 
  
Thirty-eight patients with OSA and 38 control subjects were studied. The main clinical and 
biochemical characteristics are shown in Table 1. By design, characteristics of patients, 
including age, sex, BMI and the prevalence of metabolic syndrome, were similar between 
patients and controls. 
 
Compared with controls subjects, the OSA patients showed elevated plasma levels of I-FABP 
(Table 1). Participants were divided into three tertiles based on their AHI (AHI <7.5, n=25; 
AHI 7.6-28.5, n=26; AHI >28.6, n=25). There was a significant trend of increasing I-FABP 
levels with increasing AHI (ptrend 0.049) (Fig. 1). 
 
Multivariate analysis showed that there were no significant associations between  
 I-FABP levels and indices of nocturnal hypoxia (mean and minimal nocturnal oxygenation 
saturation) after adjustment for other variables. No significant differences in zonulin levels 
were detected between OSA patients and controls (Table 1). 
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Significant associations between zonulin levels and waist circumference, glucose and insulin 
were detected both in controls and patients with OSA. In addition, in the OSA group, zonulin 
levels correlated negatively with the mean nocturnal oxygenation saturation and positively 
with total cholesterol, ALT, AST, GGT and hs-CRP (Table 2). The associations between 
zonulin and ALT, AST and hs-CRP were attenuated, but not eliminated, after adjustment for 
age, sex, BMI and components of metabolic syndrome in multivariate analysis (Table 3). 
 
Discussion 
This study showed that: (1) the I-FABP levels were elevated in patients with OSA, 
suggesting that OSA itself is a risk factor for intestinal damage; (2) the zonulin levels were 
associated with the presence of obesity and metabolic disturbances both in OSA and non-
OSA patients; (3) among the OSA patients, zonulin levels were positively correlated with 
aminotransferases levels, suggesting a possible link between intestinal permeability and 
nonalcoholic fatty liver disease (NAFLD).  
 
Intestinal fatty acid binding proteins are small cytosolic proteins present in mature 
enterocytes and they are released into the circulation upon membrane integrity loss [6,17].
 
Previous studies have reported on the value of I-FABP as a biomarker for intestinal ischemia, 
and a relationship between plasma I-FABP levels and the degree of ischemic periods has 
been detected [18].
 
In the present study, despite the similar anthropometric and metabolic 
characteristics between the OSA participants and controls, the I-FABP levels were higher in 
the OSA group and tended to increase with an increasing AHI, suggesting an intestinal 
epithelial injury in these patients. The cyclical changes of hypoxemia with reoxygenation 
could represent an important mechanism for the presence of intestinal damage in OSA, 
independent of metabolic disturbances. Disruption of the gut wall integrity and leakage of 




macromolecules and microbial products from the intestinal lumen into the circulation can 
induce local and systemic inflammatory responses [19-21].
 
The present results suggest that 
OSA might contribute to gut mucosal injury, which might have important clinical 
implications. Assessment of plasma I-FABP offers the possibility to monitor the presence of 
intestinal ischemia, and several studies have shown their clinical usefulness as a marker for 
epithelial intestinal damage and their prognostic value for adverse outcomes [6,11-13,17].
 
  
In the present study, it was also observed that the zonulin levels were not significantly 
different between patients with OSA and controls without OSA of similar metabolic profile. 
Recent studies have suggested a role for increased intestinal permeability in the genesis of 
obesity and metabolic disorders [6,14,22].
 
Zonulin regulates intestinal permeability by 
modulating intercellular tight junctions, and higher zonulin levels have been detected in the 
obese and those with impaired glucose tolerance [8,23-25].
 
In the present study, circulating 
zonulin concentrations were correlated with obesity-related disturbances (waist 
circumference, glucose, insulin and total cholesterol) both in OSA and non-OSA subjects. 
These results suggest that sleep apnea does not have any direct effect on the circulating 
zonulin concentrations. Nevertheless, although the present results suggest that the effects on 
zonulin concentrations and intestine permeability may be dependent on obesity index or 
metabolic dysfunction, rather than on sleep apnea by itself, does not mean that they are 
irrelevant in the pathogenesis of several complications in these patients. There is now 
evidence that interactions between gut microbiota and other intestinal factors are emerging 
mechanisms influencing the onset of NAFLD [26].
 
In this sense, a recent study has shown 
that in subjects with NAFLD, circulating zonulin was increased in association with the 
severity of steatosis, providing a possible link between intestinal permeability and the 
development of NAFLD [15].
 
In parallel with these studies, evidence is growing that OSA is 




an independent factor for NAFLD [27,28].
 
The present study showed that among OSA 
patients, zonulin was also associated with aminotransferases (AST, ALT) and GGT, which 
are the main tests used to assess liver injury and surrogate markers of NAFLD, the hepatic 
manifestation of metabolic syndrome. These observations suggest a potential role of the 
zonulin system in the link between OSA and liver injury, raising the possibility that the 
influence of sleep apnea on liver dysfunction liver may particularly vary as a function of their 
degree of intestine permeability independently of obesity or metabolic conditions. 
 
The strengths of this study included the assessment of associations between circulating 
concentrations of I-FABP (marker of gut ischemia) and zonulin (marker and modulator of 
intestinal permeability) with OSA and the presence of metabolic syndrome. Taken together, 
the present findings suggest that the effects of OSA on gut barrier markers (I-FABP and 
zonulin) may represent different underlying pathways, with OSA likely acting through 
ischemic periods, and gut mucosal damage and the zonulin system having a more important 
effect on the liver consequences via intestinal permeability.  
 
Several limitations should be considered. First, the main limitation was the relatively small 
number of participants. Despite the study design and the metabolic similarity between OSA 
and controls, the lack of power to detect differences between these two groups cannot be 
excluded. The observation of a non-significant trend of an independent association between I-
FABP levels and indices of nocturnal hypoxia may have been due to the lack of power to 
detect this difference. Second, although AHI reflects OSA severity, an additional estimation 
of the oxygen desaturation index could have reinforced the relative role of OSA on gut 
barrier integrity markers. Third, the cross sectional nature of the study did not prove cause-
effect relationships between OSA and gut barrier markers. Finally, the plasma levels of I-
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FABP and zonulin after CPAP were not measured, and this may have been a limitation in the 
assessment of the independent effects of OSA on these markers.  
 
Conclusions 
The results of this study showed that I-FABP levels were elevated in patients with OSA,  
suggesting that OSA itself is a risk factor for intestinal damage. Zonulin levels were 
associated with the presence of obesity and metabolic disturbances both in OSA and non-
OSA patients. In addition, among the OSA patients, zonulin levels were positively correlated 
with aminotransferases levels, suggesting a possible link between intestinal permeability and 
nonalcoholic fatty liver disease.  
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 Fig. 1. I-FABP levels according to the apnea-hypopnea index (AHI). 
 





Age (years) 49±12 50±12 
Men (%) 19 (50%)  21 (52%)  
BMI (kg/m) 29±6 28±6 
Waist circumference (cm) 96 ±13 95±12 
Hypertension (%) 4 (11%) 12 (32%)* 
Diabetes (%) 2 (5%) 1 (3%)  
Metabolic syndrome (%)  14 (37 %) 14 (37%)  





) 5.7±2.6 45.5±29 * 
Mean SaO2 (%)  95±2 93±4 * 
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Minimal SaO2 (%) 90±4                82±9 * 
Glucose (mg/dL) 99 ±17                98±7  
Triglycerides (mg/dL) 127±48              133±44 
Cholesterol (mg/dL) 199±41 200±47 
HDLc (mg/dL) 54±17 56±17 
Creatinine (mg/dL) 0.87±0.2 0.85±0.2 
Insulin (µUI/mL) 9.6±6.5 9.9±7.2 
AST (U/L) 19 (16-22) 21 (17-25) 
ALT (U/L) 21 (14-27) 23 (16-29) 
GGT (U/L) 22 (13-37) 21 (14-38) 
hs-CRP (mg/L) 0.2 (0.1-0.4) 0.2 (0.1-0.5) 
zonulin (ng/mL) 4.5 (3.7-5.3) 4.2 (3.3-4.9) 
I-FBAP (pg/mL) 396 ( 234-559)  571 (290-950)* 




Table 2. Correlation coefficients for the association of zonulin in controls and OSA patients. 
 Controls OSA 
 R p R p 
Waist circumference (cm) 
 
0.382 0.04 0.442 0.004 
Glucose (mg/dL) 0.343 0.035 0.321 0.04 
Insulin (µUI/mL) 0.328 0.041 0.351 0.03 
Cholesterol (mg/dL) 0.135 0.419 0.397 0.011 
Mean SaO2 (%) –0.315 0.061 –0.378 0.019 
ALT (U/L) 0.001 0.996 0.484 0.002 
AST (U/L) –0.006 0.972 0.426 0.006 
GGT (U/L) 0.158 0.343 0.444 0.004 
hs-CRP (mg/L) 0.320 0.054 0.372 0.02 
Table 3. Multivariate analysis of factors associated with zonulin in OSA patients 
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 β 95% CI (β) p 
Mean SaO2 (%) 0.008 –0.049-0.034 0.711 
Cholesterol (mg/dL) 0.001 –0.001-0.003 0.267 
ALT (U/L) 0.014 0.001-0.028 0.04 
AST (U/L) 0.02 0.002-0.037 0.04 
GGT (U/L) 0.01 –0.005-0.008 0.681 
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